BDTX•benzinga•
Black Diamond Therapeutics And Servier Announce A Global Licensing Agreement For BDTX-4933 For Solid tumors; Servier Will Develop And Commercialize BDTX-4933, Black Diamond To Receive $70M Upfront Payment And Up To $710M In Milestones
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 19, 2025 by benzinga